Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

(2020) Franck E Nicolini et al.   BLOOD

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

(2020) Andreas Hochhaus et al.   BLOOD

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors

(2017) Ami B. Patel et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

(2017) Andreas Hochhaus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

(2015) L Kalmanti et al.   LEUKEMIA

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

(2015) Stéphane Prost et al.   NATURE

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo

(2014) P. Gallipoli et al.   BLOOD

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase

(2014) Michael Lauseker et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

(2013) E. Bolton-Gillespie et al.   BLOOD

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

(2011) A. Fabarius et al.   BLOOD

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

(2011) E. Jabbour et al.   BLOOD

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

(2011) Hagop M Kantarjian et al.   LANCET ONCOLOGY

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE